Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Bone Scan Index and Progression-free Survival Data for Progressive Metastatic Castration-resistant Prostate Cancer Patients Who Received ODM-201 in the ARADES Multicentre Study.

Reza M, Jones R, Aspegren J, Massard C, Mattila L, Mustonen M, Wollmer P, Trägårdh E, Bondesson E, Edenbrandt L, Fizazi K, Bjartell A.

Eur Urol Focus. 2016 Dec;2(5):547-552. doi: 10.1016/j.euf.2016.01.005. Epub 2016 Feb 3.

2.

Bone Scan Index as an Imaging Biomarker in Metastatic Castration-resistant Prostate Cancer: A Multicentre Study Based on Patients Treated with Abiraterone Acetate (Zytiga) in Clinical Practice.

Reza M, Ohlsson M, Kaboteh R, Anand A, Franck-Lissbrant I, Damber JE, Widmark A, Thellenberg-Karlsson C, Budäus L, Steuber T, Eichenauer T, Wollmer P, Edenbrandt L, Trägårdh E, Bjartell A.

Eur Urol Focus. 2016 Dec;2(5):540-546. doi: 10.1016/j.euf.2016.02.013. Epub 2016 Mar 9.

PMID:
28723520
3.

A Preanalytic Validation Study of Automated Bone Scan Index: Effect on Accuracy and Reproducibility Due to the Procedural Variabilities in Bone Scan Image Acquisition.

Anand A, Morris MJ, Kaboteh R, Reza M, Trägårdh E, Matsunaga N, Edenbrandt L, Bjartell A, Larson SM, Minarik D.

J Nucl Med. 2016 Dec;57(12):1865-1871. Epub 2016 Jul 21.

4.

Bone Scan Index as a prognostic imaging biomarker during androgen deprivation therapy.

Reza M, Bjartell A, Ohlsson M, Kaboteh R, Wollmer P, Edenbrandt L, Trägårdh E.

EJNMMI Res. 2014 Oct 17;4:58. doi: 10.1186/s13550-014-0058-y. eCollection 2014.

Supplemental Content

Loading ...
Support Center